Diligence memo · auto-generated · as of July 2, 2026

BioSynchronicity Corp

BioSynchronicity Corp looks under-valued against its niche peers and is active on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

BioSynchronicity Corp operates in Biotechnology, based in SPOKANE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

BioSynchronicity Corp has raised $1.3M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.3M on 2024-07-22.

Most recent recorded round closed around 2025-12-02.

Valuation (modeled)modeled

Provath models BioSynchronicity Corp at approximately $2.2M (range $720K–$4.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.48× the median modeled value of Seed Biotechnology companies in 2025–2027 (99 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 19 months.

Last raise 7 mo ago; this sector typically re-raises about every 14 months.

Raising on or ahead of the sector's normal rhythm.

The last round was 1.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 21% of Biotechnology peers (4293 compared).

Modeled value ranks above 6% of those peers.

Closest niche peers: Carna Inc., NRX Pharmaceuticals, Inc., Vicora, Inc., MH3D, Inc., Oral Genome Corp..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.